secwatch.observer — SEC 8-K summary
======================================

Issuer:     MBX Biosciences, Inc. (MBX)
CIK:        0001776111
Form:       8-K
Filed at:   2025-04-07T23:59:59+00:00
Accession:  0000950170-25-051371
Event type: leadership
Sentiment:  positive
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MBX Biosciences appoints Steve Hoerter to board of directors
------------------------------------------------------------

- Steven L. Hoerter appointed as independent director effective April 7, 2025.
- Board expanded from 8 to 9 members; Hoerter designated as Class III director until 2027 AGM.
- Hoerter is former CEO of Deciphera Pharmaceuticals (acquired by Ono for $2.4B in 2024).
- Brings 30+ years pharma commercialization experience; also serves on boards of ORIC Pharmaceuticals and C4 Therapeutics.
- Will receive standard non-employee director compensation and enter indemnification agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1776111/000095017025051371/0000950170-25-051371-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1776111/000095017025051371/mbx-20250407.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-051371

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer